Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy.
复制标题
靶向双重肿瘤相关抗原在癌症治疗中的双特异性抗体。
DOI：
10.1007/s00432-020-03404-6
复制
发表时间：
2020-12
影响因子：
3.6
通讯作者：
van Elsas A
中科院分区：
文献类型：
--
作者：
Huang S;van Duijnhoven SMJ;Sijts AJAM;van Elsas A
双特异性抗体（BsAb）已经成为癌症治疗的主要药物类别，并且对于治疗应用越来越感兴趣。截至2020年4月，超过123种BsAbs正在接受肿瘤学临床评估（包括两种已上市的BsAbs Blinatumomab和Catumaxomab）。大多数（123个中的82个）在临床评估中的BsAb可以被归类为双特异性免疫细胞标记物，而第二个较少讨论的BsAb亚类靶向两种肿瘤相关抗原（TAA）。在这篇综述中，我们总结了双TAA靶向BsAbs的临床发展，并提供了设计双TAA靶向BsAbs时的关键考虑因素的概述。本文使用PubMed和ClinicalTrials.gov数据库检索了截至2020年4月1日以英文发表的相关文献和临床试验。如果BsAbs的临床试验在2018年之前没有终止、撤回或完成而没有报告结果，则认为其在临床上是活跃的。通过搜索ClinicalTrials.gov遗漏的数据是手动管理的。靶向BsAb的双重TAA提供了几个优点，包括增加的肿瘤选择性，同时调节肿瘤细胞中两种功能途径的潜力，并可产生改善的有效载荷递送。靶向BsAb的双重TAA代表一类有价值的生物制剂，并且早期临床研究已经证明了在血液恶性肿瘤和实体瘤中有希望的抗肿瘤功效。
Bispecific antibodies (BsAbs) have emerged as a leading drug class for cancer therapy and are becoming increasingly of interest for therapeutic applications. As of April 2020, over 123 BsAbs are under clinical evaluation for use in oncology (including the two marketed BsAbs Blinatumomab and Catumaxomab). The majority (82 of 123) of BsAbs under clinical evaluation can be categorized as bispecific immune cell engager whereas a second less well-discussed subclass of BsAbs targets two tumor-associated antigens (TAAs). In this review, we summarize the clinical development of dual TAAs targeting BsAbs and provide an overview of critical considerations when designing dual TAA targeting BsAbs. Herein the relevant literature and clinical trials published in English until April 1st 2020 were searched using PubMed and ClinicalTrials.gov database. BsAbs were considered to be active in clinic if their clinical trials were not terminated, withdrawn or completed before 2018 without reporting results. Data missed by searching ClinicalTrials.gov was manually curated. Dual TAAs targeting BsAbs offer several advantages including increased tumor selectivity, potential to concurrently modulate two functional pathways in the tumor cell and may yield improved payload delivery. Dual TAAs targeting BsAbs represent a valuable class of biologics and early stage clinical studies have demonstrated promising anti-tumor efficacy in both hematologic malignancies and solid tumors.
登录
查看更多内容
影响因子：
5.7
作者：
de Goeij, Bart E. C. G.;Vink, Tom;Parren, Paul W. H. I.
通讯作者：
Parren, Paul W. H. I.
DOI：
10.1158/1078-0432.ccr-14-2877
发表时间：
2015-03-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Bachanova V;Frankel AE;Cao Q;Lewis D;Grzywacz B;Verneris MR;Ustun C;Lazaryan A;McClune B;Warlick ED;Kantarjian H;Weisdorf DJ;Miller JS;Vallera DA
通讯作者：
Vallera DA
影响因子：
5.3
作者：
Grugan KD;Dorn K;Jarantow SW;Bushey BS;Pardinas JR;Laquerre S;Moores SL;Chiu ML
通讯作者：
Chiu ML
DOI：
10.1073/pnas.0710370104
发表时间：
2007-12-26
影响因子：
11.1
作者：
Bean, James;Brennan, Cameron;Pao, William
通讯作者：
Pao, William
影响因子：
5.3
作者：
Gong, Shiyong;Ren, Fang;Wu, Chengbin
通讯作者：
Wu, Chengbin